Amgen Inc.
AMGN
Ci-dessous : le cours en direct de Amgen Inc. (AMGN), un graphique 1 an, 8 indicateurs (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume) et le mode de comparaison. Ajoutez à votre portefeuille, mettez en favori ou définissez des alertes de prix.
Amgen Inc. (AMGN) est une entreprise du secteur Healthcare basée en United States. Active dans Drug Manufacturers - General, elle emploie environ 31,500 personnes. Sur l'année écoulée, AMGN a évolué entre 269.77 et 391.29 USD. Le PER (TTM) avoisine 25.51 pour une capitalisation d'environ 197.69B USD. Le rendement en dividendes actuel est de 2.75%.
- Prev close
- $371.58
- Volume (24h)
- $1.05B
- Market cap
- $197.69B
- Currency
- USD
Score
45/ 100 · Mitigé
- Valeur27
- Qualité83
- Momentum49
- Croissance36
- Risque50
- Dividende44
- Liquidité26
Composé à partir de données de marché publiques. Informatif uniquement — pas un conseil en investissement.
Projection de tendance
Là où la tendance récente pointe si elle se poursuit.
- +5 barres
- 368.725 +0.66%
- +20 barres
- 372.1112 +1.59%
- +60 barres
- 373.4295 +1.95%
- +120 barres
- 373.478 +1.96%
Continuation par régression linéaire — pas une prédiction, pas un conseil en investissement. ±1σ ≈ 68% · ±2σ ≈ 95%: ±0.0246 USD.
Interprétation
Les signaux composites paraissent mitigés. Force : qualité avec faiblesse : liquidité du bilan. Le prix est près du tiers supérieur de la plage récente, la tendance est ascendante.
Observation descriptive — ce n'est pas un conseil en investissement.
Décomposition du score
Les valeurs brutes derrière chaque pilier pour voir ce que le score composite mesure.
- Valeur27/100
Valeur semble fragile — porté par PER (25.51).
PER:25.51P/B:21.51PEG:2.01 - Qualité83/100
Qualité semble solide — porté par ROE (101.32%).
ROE:101.32%ROA:8.35%Marge nette:20.96%Marge brute:71.44% - Momentum49/100
Momentum semble mitigé — porté par Variation 52 sem (23.80%).
Variation 52 sem:23.80% - Croissance36/100
Croissance semble faible — porté par Croissance CA (5.80%).
Croissance CA:5.80%Croissance BPA:4.40% - Risque50/100
Risque semble mitigé — porté par Dette / capitaux (623.75).
Bêta:0.4Dette / capitaux:623.75Intérêts à découvert:2.39% - Dividende44/100
Dividende semble faible — porté par Taux de distribution (67.22%).
Rendement dividende:2.75%Taux de distribution:67.22% - Liquidité26/100
Liquidité semble fragile — porté par Ratio courant (1.26).
Ratio courant:1.26Ratio rapide:0.85
Calculé à partir de données de marché publiques — informatif, pas un conseil en investissement.
Niveaux de référence
Retracements et extensions de Fibonacci sur la plage récente.
Référence uniquement — ce n'est pas un conseil en investissement.
Ces coordonnées décrivent les regroupements de prix passés, pas où acheter ou vendre. Faites vos propres recherches avant toute transaction.
- RésistanceExtension Fib +161.8%472.4164 USD+28.97% du prix actuel
- RésistanceExtension Fib +100%436.56 USD+19.18% du prix actuel
- RésistanceExtension Fib +61.8%414.3964 USD+13.13% du prix actuel
- RésistanceExtension Fib +27.2%394.3215 USD+7.65% du prix actuel
- Actuel366.29 USD
- SupportRetracement Fib 23.6%364.8473 USD-0.39% du prix actuel
- SupportRetracement Fib 38.2%356.3764 USD-2.71% du prix actuel
- SupportPoint médian Fib 50%349.53 USD-4.58% du prix actuel
- SupportRetracement Fib 61.8%342.6836 USD-6.44% du prix actuel
- SupportRetracement Fib 78.6%332.9363 USD-9.11% du prix actuel
- SupportExtension Fib −27.2%304.7385 USD-16.80% du prix actuel
- SupportExtension Fib −61.8%284.6636 USD-22.28% du prix actuel
- SupportExtension Fib −100%262.5 USD-28.34% du prix actuel
Financials
- 52w high
- $391.29
- 52w low
- $269.77
- 52w change
- 23.80%
- Day high
- $378.54
- Day low
- $361.74
- P/E (TTM)
- 25.51
- Forward P/E
- 15.62
- PEG
- 2.01
- Price / Book
- 21.51
- Beta (5Y)
- 0.4
- Enterprise value
- 242.97B
- EV / Revenue
- 6.53
- EV / EBITDA
- 14.36
- EPS (TTM)
- $14.36
- Forward EPS
- $23.45
- Dividend yield
- 2.75%
- Dividend rate
- $10.08
- Payout ratio
- 67.22%
- Revenue (TTM)
- 37.22B
- EBITDA
- 16.92B
- Free cash flow
- 7.44B
- Total cash
- 12.04B
- Total debt
- 57.32B
- Debt / Equity
- 623.75
- Current ratio
- 1.26
- Quick ratio
- 0.85
- Profit margin
- 20.96%
- Gross margin
- 71.44%
- Return on assets
- 8.35%
- Return on equity
- 101.32%
- Shares outstanding
- 539.71M
- Float
- 538.22M
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Analyst & Risk
- Beta (vs S&P 500)
- 0.4
- very stable
- 52-week change
- 23.80%
- Short % of float
- 2.39%
- Short ratio (days)
- 4.09
- Debt / Equity
- 623.75
- very high leverage
- Current ratio
- 1.26
- Quick ratio
- 0.85
- ROE
- 101.32%
- ROA
- 8.35%
- PEG ratio
- 2.01
- richly valued
- EV / Revenue
- 6.53
- EV / EBITDA
- 14.36
- Revenue growth
- 5.80%
- Earnings growth
- 4.40%
- EBITDA
- 16.92B
- Free cash flow
- 7.44B
- Total cash
- 12.04B
- Total debt
- 57.32B
- Insider holdings
- 0.22%
- Institutional
- 86.52%
Recent rating changes
- 2026-07-13UBSBuy → Buymain
- 2026-07-13GuggenheimNeutral → Neutralmain
- 2026-07-08Morgan StanleyEqual-Weight → Equal-Weightmain
- 2026-07-07Truist SecuritiesHold → Holdmain
- 2026-07-06Cantor FitzgeraldNeutral → Neutralreit
- 2026-06-16MizuhoNeutral → Neutralmain
- 2026-06-10Morgan StanleyEqual-Weight → Equal-Weightmain
- 2026-05-14Piper SandlerOverweight → Overweightmain
Financial documents
- Annual report of employee stock purchase11-K2026-06-11
- Corporate Changes & Voting Matters8-K2026-05-20
- Corporate Changes & Voting Matters8-K2026-05-19
- Periodic Financial Reports10-Q2026-05-01
- Corporate Changes & Voting Matters8-K2026-04-30
- Corporate Changes & Voting Matters8-K2026-04-22
- Proxy StatementsDEFA14A2026-04-21
- Proxy StatementsDEFA14A2026-04-15
- Proxy StatementsDEF 14A2026-04-07
- Annual Report to ShareholdersARS2026-03-31
- Corporate Changes & Voting Matters8-K2026-02-19
- Periodic Financial Reports10-K2026-02-13
Actualités récentes
- Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?Motley Fool2h ago
- What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.Barrons.com3h ago
- IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?Motley Fool22h ago
- IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?Motley Fool1d ago
- The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?24/7 Wall St.2d ago
- Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?Zacks3d ago
- MRK Stock Jumps on FDA Nod for Cholesterol-Lowering PillZacks2d ago
- Seagate Stock And The Bet On A Denser FutureTrefis2d ago
Associés
Autres actifs de cette catégorie.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Discussion en direct
Connexion to join the discussion.
- Aucun commentaire. Soyez le premier.